長春高新(000661.SZ)放量收跌5.72% 較歷史高位已回調超30%
格隆匯9月16日丨長春高新(000661.SZ)今日再度掉頭向下,收跌5.72%報361.45元,成交54.87億元,成交額連續第三日放大,最新總市值1463億元。該股今日盤中一度跌8.57%至350.51元,距離8月4日創出的歷史最高價513.5元回調31.74%。長春高新下跌的同時,今日疫苗股全線走低,西藏藥業、康華生物跌幅均在5%以上。9月14日網絡流傳的一份長春高新核心子公司金賽藥業的調研紀要,訪談嘉賓顯示是金賽藥業創始人金磊。這份調研經要被認為是引發長春高新股價跌停的重要因素之一。長春高新也因涉嫌信披違規遭到投資者質疑,同時也已引發監管關注,深交所昨日已發函關注。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.